WINDSOR, Conn., Feb. 14 /PRNewswire/ -- Protedyne Corporation, a leading laboratory automation supplier, today announced it has completed the installation and site acceptance of its BioCube System LX 2000 at Correlagen Diagnostics. Correlagen selected the BioCube System to automate their Genes That Matter(TM) gene testing service. The BioCube System will optimize their clinical workflow for throughput, analytical procedures, and data handling needs. The BioCube System will integrate PCR setup, PCR cleanup, sequencing reaction setup, and sequencing reaction cleanup in a continuous process.
"We are pleased to have provided Correlagen with technology that addresses their need to automate complex testing protocols as well as the throughput requirements for their molecular diagnostic test menu," said Fran Tutttle, President and CEO of Protedyne. "We look forward to being a part of their future success."
"Protedyne's BioCube System is proving to be an excellent platform for implementing Correlagen's software and gene sequencing methods. Our throughput, quality, and costs are unmatched, and the BioCube System is a major component of our success," said David Margulies, M.D., CEO of Correlagen. Correlagen's alliance program with academic and pharmaceutical collaborators is based in large part on the capabilities we have created on this automated platform," added Joyce Samet, Senior Vice President. "Correlagen looks forward to extending our relationship with Protedyne."
Protedyne's unique approach combines scientific and automation expertise, industrial-quality automation, and sophisticated data management. The foundation of the company is the BioCube System, which brings advanced industrial automation capabilities into life science and diagnostic laboratories in a fast, flexible, and reliable package. Protedyne is headquartered in Windsor, Connecticut. For more information call (860) 683- 1860 in North America or visit Protedyne on the web at http://www.protedyne.com.
Correlagen Diagnostics, Inc. develops and commercializes genetic testing services using a high throughput automated approach that incorporates sequencing, variant analysis and results reporting. By focusing on Genes That Matter(TM) -- where variation is correlated with disease and where testing would impact diagnosis and treatment -- Correlagen is accelerating and increasing the use of genetic testing in clinical practice. Correlagen Diagnostics is based in Cambridge, Massachusetts. http://www.correlagen.com.
Contact: Patti Dinneen